# Molecular-Guided Therapy for Melanoma in Canada: Overview of Current Practices and Recommendations

## TL;DR

This paper reviews current practices of molecular testing for melanoma in Canada and suggests standardizing testing to improve patient care.

## Contribution

The paper proposes standardized criteria for reflex biomarker testing in melanoma to align with clinical guidelines and optimize healthcare resources.

## Key findings

- Current reflex biomarker testing for melanoma in Canada lacks standardization and awareness.
- Proposed criteria prioritize melanomas with Breslow thickness >4 mm or disseminated disease for molecular testing.
- Ancillary tests like BRAF VE1 immunohistochemistry and next-generation sequencing are highlighted for clinical relevance.

## Abstract

The emergence of pathologist-driven molecular reflex testing for tumoural biomarkers is a significant advancement in cancer diagnostics, facilitating targeted cancer therapy for our patients. Based on our experience, the Canadian landscape of pathologist-driven reflex biomarker testing for melanoma lacks standardization and is plagued by a lack of awareness by pathologists and clinicians. This paper comprehensively examines the approaches to reflex biomarker testing for melanoma patients across Canada, highlighting the regional variations in the criteria for initiating molecular testing, the biomarkers tested, and the molecular techniques employed. We also discuss the clinical relevance of biomarkers, emphasizing their alignment with the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as well as ancillary tests such as BRAF VE1 immunohistochemistry to detect BRAF V600E mutation and molecular techniques such as real-time polymerase chain reaction, matrix-assisted laser desorption ionization-time of flight mass spectrometry and next-generation sequencing. Our proposed standardized minimum criteria for reflex testing prioritize melanomas with Breslow thickness >4 mm or disseminated disease, who will most benefit from enhanced delivery of biomarkers and expedited access to targeted therapies while attempting to balance cost-effectiveness and utilization of public healthcare resources with patient outcomes.